Femtech KOVE medical eyes First in Human study after CHF1.6 million seed round
KOVE Medical, a Zurich-based spin‑off from the University of Zurich, has raised CHF 1.6 million in a seed round to develop an implantable device that closes the defect created by fetoscopic surgery, thereby reducing the risk of preterm birth. The device aims to make in‑utero surgeries safer and enable more widespread use of fetoscopies to treat life‑threatening fetal conditions. The company plans to use the new funds to advance to first‑in‑human studies.
KOVE Medical, a Zurich-based spin‑off from the University of Zurich, has raised CHF 1.6 million in a seed round to develop an implantable device that closes the defect created by fetoscopic surgery, thereby reducing the risk of preterm birth. The device aims to make in‑utero surgeries safer and enable more widespread use of fetoscopies to treat life‑threatening fetal conditions. The company plans to use the new funds to advance to first‑in‑human studies.
It exemplifies Swiss innovation in medical technology, highlighting the potential for future AI integration in advanced fetal care solutions.
Original source record. Open the original record to verify the underlying announcement.